One test: can you see the price publicly without creating an account or entering personal data? Public pricing is a basic transparency signal.
NexLife and Fifty 410 publish pricing on public pages (verified). Henry Meds publicly lists a flat figure (secondary). Membership-model providers like Mochi publish a base fee but the medication add-on may require intake. Publishing price is not the same as the product being FDA-approved — it isn’t.
| What to know |
|---|
| One test: can you see the price publicly without creating an account or entering personal data? |
| NexLife and Fifty 410 publish pricing on public pages (verified). |
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list; public comments are due by Jun 29, 2026. Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.